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Summary
L-4 directs mouse and human B cells to produce, respec-
tively, IgG1 and IgE or IgG4 and IgE (1-6). Recently,
we (7) and others (8) cloned and expressed another T cell-
derived cytokine (IL-13). As with IL-4, IL-13 induces human
B cells to switch to IgG4 and IgE production in an IL-4-
independent fashion (7-9, 10). IL-13 shares many other prop-
erties with IL-4. Like IL-4, it has growth-promoting effects
on preactivated B cells (7, 9) and it suppresses the produc-
tion of the proinflammatory rytokines (IL-la, (3, IL-6, IL-8,
and TNF-ca) and other monokines (GM-CSF, M-CSF, GCSF,
IL-10, and IL-12) by activated monocytes, whereas, it enhances
the production of the IL-1R antagonist (10a). In addition,
IL-13 modulates the expression of various surface molecules
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Interleukin 4 (IL-4) and IL-13 share many biological functions. Both rtokines promote growth
of activated human B cells and induce naive human surface immunoglobulin D+ (sIgD+) B
cells to produce IgG4 and IgE. Here we show that a mutant form of human IL-4, in which
the tyrosine residue at position 124 is replaced by aspartic acid (hIL-4Y124D), specifically blocks
IL-4 and IL-13-induced proliferation ofB cells costimulated by anti-CD40 mAbs in a dose-dependent
fashion. A mouse mutant IL-4 protein (mIL-4Y119D), which antagonizes the biological activity
of mouse IL-4, was ineffective. In addition, hIL-4Y124D, at concentrations of up to 40 nM,
did not affect IL-2-induced B cell proliferation. hIL-4Y124D did not have detectable agonistic
activity in these B cell proliferation assays. Interestingly, hIL-4Y124D also strongly inhibited
both IL-4 or IL-13-induced IgG4 and IgE synthesis in cultures of peripheral blood mononuclear
cells, or highly purified sIgD ` B cells cultured in the presence of anti-CD40 mAbs. IL-4 and
IL-13-induced IgE responses were inhibited >95% at a N50- or -20-fold excess ofhIL-4Y124D,
respectively, despite the fact that the IL-4 mutant protein had a weak agonistic activity. This
agonistic activity was 1.6 ± 1.9% (n = 4) of the maximal IgE responses induced by saturating
concentrations of IL-4. Taken together, these data indicate that there are commonalities between
the IL-4 and IL-13 receptor. In addition, since hIL-4Y124D inhibited both IL-4 and IL-13-induced
IgE synthesis, it is likely that antagonistic mutant IL-4 proteins may have potential clinical use
in the treatment of IgE-mediated allergic diseases.
on B cells and monocytes associated with functions of these
cells (9, l0a).
Despite having only x+30% homology with IL-4, IL-13
shares structural homologies with IL-4 and other rtokines,
such as IL-2, growth hormone, GM-CSF and M-CSF, which
all have a four-helix bundle motif, consisting offour antiparallel
a helices (11-14). The receptors of these rytokines are also
structurally related (15-17). Amino acid residues involved in
receptor binding in several ofthe ligands of this receptor family
have been determined (18-20). Extensive mutational substi-
tution analysis of mouse IL-2 has indicated that replacement
of one amino acid residue (Glu 141-Asp) at the COOH
terminus of the fourth a helix results in a loss of receptor
activation, whereas most of its receptor binding capacity is
preserved (18). Based on the structural homology between
IL-2 and IL-4 (12-14) a residue analogous to mIL-2 Glu 141
was found in human IL-4 (21, 22). Substitution of Tyr 124
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hIL-4, results in high affinity receptor binding, but not in
receptor activation (21, 22). Because ofthese properties, hIL-4
Tyr 124-Asp (designated hIL-4Y124D) was shown to an-
tagonize IL-4-induced CD23 expression on human B cells (21).
In this study, we investigated the capacity ofhIL-4Y124D
to antagonizetwo major biological functions ofIL-4 and IL-
13, namely their B cell growth-promoting effects and their
induction of IgG4 and IgE synthesis. We demonstrated that
the IL-4 mutant Y124D blocks both IL-4 and IL-13-induced
B cell proliferation and IgG4 and IgE synthesis, in a dose-
dependent fashion. The capacity of hIL-4Y124D to inhibit
the biological activities of both IL-4 and IL-13 has impor-
tant consequences for the therapeutic potential of this an-
tagonist in the treatment of IgE-mediated allergic diseases.
Materials and Methods
Cells.
￿
Highly purified B cells were isolated from normal human
spleens obtained from cadaver donors, as previously described (9,
23). Briefly, splenocytes were stained for 30 min on ice with the
followingPE-conjugated mAbs: anti-CD3, -CD4, -CD8, -CD14,
-CD16, and -CD56 (Becton Dickinson & Co., SanJose, CA). The
cells were then washed once in medium, centrifuged over Histo-
paque 1077 (Sigma Chemical Co., St. Louis, MO), and washed
twice in PBS. The stained splenocytes were negativelysorted with
a FACStar Plus® (Becton Dickinson & Co.). An aliquot of the sorted
cells was reanalyzedby FRCS® after staining with CD20-FITC (anti-
Leu16) or an isotype control mAb. The sorted cells were always
>98% CD20+ . In other experiments, surface (s)IgD+ B cells were
obtained by two-color sorting of splenocytes labeled for negative
sorting as above, followed by anti-hIgD-FITC mAb (Nordic, Til-
burg, The Netherlands). slgD* cells were obtained by sorting the
PE-negative and FITC-positive cells, as described (9). Reanalysis
of the sorted cells showed that they were >99.5% sIgD*. Blood
samples were obtained from healthy volunteers, and PBMC were
isolated by centrifugation over Histopaque 1077. The cells were
then washed twice and resuspended in Yssel's medium supplemented
with 10% FCS.
Reagents.
￿
The mutant human 114 (hIL4.Y124D) which has
a single amino acid substitution at position 124 (Tyr--Asp), and
a mutant mouse IL4 protein, in which Tyr at position 119 was
replaced by Asp, were generated and purified as described (22). mIL
4Y119D protein was prepared using the same protocol as the hIL
4Y124D protein (22). Human IL13 (sp act, 5.2 x 106 U/mg) was
produced and purified as described (7). Recombinant human IL4
(sp act 10' U/mg) and 11,2 were provided by Schering-Plough Re-
search (Bloomfield, NJ). The anti-CD40 mAb 89 was a gift from
Dr. J. Banchereau (Schering-Plough, Dardilly, France). Pansor-
binTm heat-killed Staphylococcus aureus Cowan strain I cells (SaC)
was purchased from Calbiochem-Novabiochem Corp. (LaJolla, CA)
and used at a final concentration of 0.05%.
B Cell Proliferation Assay.
￿
Highly purified B cells were cultured
in U-bottom 96-well Linbro plates (Flow Laboratories Inc., McLean,
VA) at a density of 5 x 104 cells/well in Yssel's medium sup-
plemented with 10% FCS (Hyclone Laboratories, Logan, UT), in
a final volume of200,ul. Native and mutant cytokines, anti-CD40
mAb and SaC, were added in concentrations as indicated, and the
cultures were incubated at 37°C for 5 d. 1 iiCi of tritiated thymi-
dine (['H]TdR) was added to each well during the last 16 h ofcul-
ture, and the cells were harvested by a cell harvester (Skatron In-
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struments AS, Oslo, Norway) onto a filter mat. [3H]TdR activity
was measured by a beta counter (Beckman Instruments Inc.,
Fullerton, CA), after addition ofscintillation fluid. Results are ex-
pressed as mean ± SD of triplicate cultures.
Culture Conditions for Ig Production.
￿
50,000 highly purified B
cells or 105 PBMC were cocultured in Yssel's medium sup-
plemented with 10% FCS, in a final volume of 0.2 ml. Recom-
binant human 114 and 1143, human or mouse mutant 114 and
anti-CD40 mAb (20 Fog/ml) were added as indicated. Cultures were
set up in six replicates in U-bottom 96-well Linbro plates and in-
cubated 12-14 d at 37°C in 5% C02. At the end of the incuba-
tion period, the supernatants from each of the six wells were har-
vested and pooled for isotype determination.
Isotype Determination.
￿
Ig isotype production was determined
by ELISA as previously described (5, 9). The sensitivities of the
ELISA were determined with calibrated standards from Behring-
werke Ag (Marburg, Germany), and found to be 0.2 ng/ml for
IgE and IgG4, and 0.5-1 ng/ml for total IgG and IgM.
Results and Discussion
hIL-4.Y124D Inhibits both IL-4 and IL-13-induced B Cell
Proliferation. The effects of hIL-4.Y124D on IL-4 and IL-
13-induced human B cell proliferation were determined in
a culture system, in which highly purified B cells were costimu-
lated by anti-CD40 mAbs. Maximal B cell proliferation in
these cultures was obtained at saturating concentrations of
280 pM of IL-4 and 540 pM of IL-13 (Fig. 1). Although
IL-4 seemed to be slightly more potent that IL-13, the prolifer-
ative responses were generally in the same range. Addition
of various concentrations of hIL-4Y124D to these cultures
resulted in inhibition of the proliferative responses in a dose-
dependent fashion. 50% inhibition of IL-4 and IL-13-induced
B cell proliferation was generally observed at 5-10-fold excess
of hIL-4Y124D (n = 3), whereas both IL-4 and IL-13-in-
duced B cell proliferation were consistently inhibited by
,>95% at a 20-50-fold excess of hIL4Y124D. mIL4Y119D,
which antagonizes mouse IL4 activities (Zurawski, S., un-
published observations) used as control, was ineffective (Fig.
1). In addition, hIL4.Y124D tested at concentrations of up
to 40 nM failed to inhibit IL-2-induced proliferation in the
presence ofanti-CD40 mAbs and SaC (Fig. 2). hIL4Y124D
has been shown to have significant agonistic activity in in-
ducing CD23 expression on humanB cells (21), varying from
8 to 45% of the maximal CD23 content and the maximal
number of CD23+ expressing B cells, respectively (21).
However, hIL4.Y124D, even at concentrations of up to
100 nM, was unable to induce significant B cell proliferation
in the presence of anti-CD40 mAbs (data not shown).
hIL-4.Y124D Inhibits IL-4 and IL-13-induced IgG4 and IgE
Synthesis. In Fig. 3 it is shown that hIL-4Y124D inhibits,
in a dose-dependent fashion, IgG4 and IgE synthesis by PBMC
induced by various concentrations of either IL-4 or IL-13.
hIL-4.Y124D was equally effective in inhibiting IL-4- and
IL-13-induced IgG4/IgE synthesis, despite the fact that IL-13
is less potent than IL-4 in inducing Ig synthesis. Maximal
inhibition of IgE responses (>95%, n = 4) in the presence
of optimal concentrations of IL-4 and IL-13 occurred at -100-
and -20-fold excess of hIL-4Y124D, respectively. However,A
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Figure 1.
￿
Inhibition of B cell proliferation by hll,4Y124D. Highly
purified Bcells were cultured in thepresence of anti-CD40mAb and114
(280 pM)(A); or IL13 (540 pM)(B).hIl.4Y124D andmIL4Y119Dwere
addedat the onsetof thecultures at theconcentrations indicated. Results
are expressed as mean ± SD of triplicate cultures. Background prolifera-
tion ofcells(834 ± 52 cpm) in thepresence ofanti-CD40mAbsis deducted.
One of four experiments shown.
IL-4 and IL-13-induced IgG4 synthesis by PBMC, was less
effectively blocked by ML4Y124D. This may be due to the
considerably higher agonistic activity of the IL-4 mutant pro-
tein on IgG4 versus IgE production. IgE productioninduced
by hIL-4Y124D at concentrations of up to 20 nM never ex-
ceeded 5% ofthat induced by optimal concentrations of IL-4
(mean 1.6 ± 1.9, n = 4). However, the agonistic activity
of hIL-4Y124D could be as high as 25% (15.7 ± 11.4,
n = 4) of IL-4-induced IgG4 production. These differences
in the IgG4 versus the IgE-inducing capacity of hIL-4Y124D
are probably attributable to the observation that lower con-
centrations of IL-4 are required for induction of IgG4 syn-
thesis than for IgE production. Although considerable donor
variation has been observed (23), the concentrations of IL-4
or IL-13 necessary for induction of IgG4 synthesis generally
were fourfold lower than those required for induction of IgE
synthesis by PBMC (Punnonen, J., and J. E. de Vries, un-
published observations), indicating that induction of IgG4
synthesis in cultures of PBMC is a more sensitive assay. Simi-
larly, concentrations of IL-4 required for induction of op-
timal IgG1 synthesis by mouse B cells were lower than those
required for optimal IgE synthesis (24). In addition, it may
be possible that other costimulatory factors in addition to
IL-4 or IL-13 are involved in induction of IgG4 synthesis,
as has been shown for induction of IgG1 synthesis in mice
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Figure 2.
￿
Effects of hIL4Y124D on 114 and IL13-induced B cell
proliferation. Highly purified Bcellswere stimulated with SaC, anti-CD40
mAbs, and IL4 (280 pM) (A); 11.13 (140 pM) (B), or 11,2 (65pM) (C).
Baseline B cell proliferation (5,200 f 200 cpm) in response to SaC and
CD40 mAbs in the absenceof cytokines is represented by thehorizontal
line; (-0-) hIL4Y124D; (--~--) mIL4Y119D.
with disrupted IL-4 genes. These mice failed to produce IgE,
but still produced IgG1, although at lower levels (25).
Comparable data were obtained in culture systems, in which
highly purified s1gD+ B cells were induced to produce IgG4
and IgE by IL-4 or IL-13 in the presence ofanti-CD40 mAbs.
ML-4Y124D blocked both IL-4 and IL-13-induced IgG4 and
IgE synthesis (Fig. 4). Again, strong inhibition of both IL-4
and IL-13-induced IgG4 and IgE synthesis was observed. In-
terestingly, ML-4Y124D had no detectable agonistic activity
in this culture system, not even on IgG4 synthesis (data not
shown).
IL-4 and IL-13 share structural and functional properties
(7, 9, 10, 22). In addition, IL-4 and IL-13 have no additive
or synergistic effects on induction of IgG4 or IgE synthesisE
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Figure 3 .
￿
Effect of IL4 mutant
proteinY124D on IL4 and IIr13-in-
duced IgE and IgG4 synthesis by
human PBMC . PBMC were cul-
tured in the presence ofvarious con-
centrations of 11,4 (A and C) or IL
13 (B and D), and hIL4Y124D was
added to thecultures at the concen-
trations indicated . IgE (A and B)
and IgG4 (C and D) levels in the
culture supernatants were measured
by ELISA after a culture period of
12 d . The data represent mean Ig
levels of six replicates obtained in
Concentration ofY1240 (nM)
￿
Concentration of Y124D (nM)
￿
a representative of four experiments.
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Effects of hIL4Y124D
on IgG4 and IgE synthesisby B cells
stimulated by anti-CD40 mAbs and
11,4 or 11,13 . Highly purified
sIgD" B cells were cultured with
anti-CD40 mAbs and 11,4 (A and
C) or 11,13 (B and D) . hI1,4.Y124D
(7 nM) was added at the onset of
the cultures . IgE (A and B) and
IgG4 (C andD) concentrations were
measured at day 12 . mIL4Y119D
tested at 7nM failed to block Ig syn-
thesis induced by IL4 (280 pM) or
1143 (540 pM), data not shown .(9). These data, and the observation that hIL-4Y124D blocks
both IL-4 and IL-13-induced B cell proliferation and Ig syn-
thesis, suggest that IL-4 and IL-13 may bind to the same
receptor. However, recent studies by Zurawski et al. (22) have
shown that IL-13 does not bind to the cloned 130 kD IL-4
receptor, transfected into either mouse BaF3 cells, or monkey
COS7 cells, but it inhibits competitively the binding ofhIL-4
to functional human IL-4 receptors expressed on the IL-4-
responsive erythromyeloid leukemic cell line TF-1 (22). In
addition, in contrast to IL-4, IL-13 does not act on activated
T cells that express high levels of hIL-4R (22) . This infor-
mation, together with the present data, demonstrates that
the hIL-4R and IL-13R are distinct, complex receptors that
likely share common component(s).
One model to explain the mode of action of hIlJ4Y124D
couldbe that this mutant protein binds to the 11,4 receptor,
but fails to induce dimerization of IL4 receptors. However,
IL4 binds with a 50-100-fold higher affinity to functional
114 receptors as compared to the 130 kD IL4 binding pro-
tein expressed on heterologous cells, whereas the IL4 mu-
tant protein binds to both receptor types with the same, lower,
affinity (22). These observations argue against the lack of
dimerization of the cloned 130-kD IIr4R as a model for the
action of ML4Y124D. They are rather in support ofthe pres-
ence of an additional component(s) on cells with functional
IIr4R that is shared with IL13R, and which is required for
signaling (22). Therefore, the antagonistic effects of hIL
CY1241) on IIr13 responses could be best explained by as-
suming that binding of hIL-4Y124D to functional IL4R main-
tains a nonproductive association between the IL-4 binding
protein and the additional component(s). This nonproduc-
tive association serves to limit the supply of this additional
component(s), which is required for the formation ofproduc-
tive complexes with the putative IL13 binding protein.
It is well established that a ligand can elicit varying degrees
ofagonistic effects in different tissues (26) . The basis for this
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receptor can vary not just in receptor numbers, but also in
how efficiently they can transmit a signal, as has also been
shown for the IIL2R system (27). The expression levels of
the IL4R and I1r13R and their signal transducing capacity
may also differ depending on the mode of B cell activation.
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mAbs. In addition, they may explain why hI1r4Y124D has
agonistic activity for IgG4 productionin cultures ofPBMC,
but not for IgG4 synthesis by B cells costimulated by anti-
CD40 mAbs. Based on the above model of action of hIIr
4Y124D, the potency ofits antagonistic effects on 11,13versus
IL4 responses will depend on the relative affinities of IL4
and 11,13 for their receptors, but they may also reflect a pos-
sible diminution in the affinity of the functional IL-13R for
IIA3 via the sequestration of the additional components(s)
to a nonproductive IL4R complex. The magnitude of this
latter effect will largely depend on the relative contributions
ofthe putative IL13 binding protein and the additional com-
ponents) to binding of 1143.
The observation that IL-13, in addition to IL-4, efficiently
directs IgE switching in naive human B cells suggests that
specific IL-4 antagonists, such as anti-IL-4 mAbs or soluble
IL-4R, will be insufficient for the treatment of IgE-mediated
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